The narcolepsy therapeutics market is anticipated to witness a CAGR of nearly 9.9% during the forecast period (2022-2027).
COVID-19 has significantly impacted the market growth due to decreased adoption of narcolepsy therapeutics during the pandemic. For instance, according to the study published in the Journal of Clinical Sleep Medicine, titled 'Sleeping through a pandemic: impact of COVID-19-related restrictions on narcolepsy and idiopathic hypersomnia' in January 2022. extended sleep time, circadian delay (in Idiopathic Hypersomnia patients), and teleworking all reduced central hypersomnia symptoms. This has impacted the growth of the narcotic therapeutics market as there has been decreased consumption of narcolepsy therapeutics due to adequate sleep by people.
The increasing prevalence of narcoleptic disorders across the world, rising stress levels, growing geriatric population, and increasing awareness about various treatment options for this condition are some of the factors expected to propel the market. For instance, in the Journal of Clinical Sleep Medicine, titled 'Prevalence, incidence, and health care utilization of patients with narcolepsy: a population-representative study' in January 2022, the early incidence of narcolepsy in Europe is 0.64-1.37 per 100,000. The high incidence of this disorder will lead to increased adoption of narcolepsy therapies, thereby expected to drive the market growth over the forecast period.
In addition, according to the study published in Current Sleep Medicine Reports, titled 'Narcolepsy Presentation in Diverse Populations: an Update' in November 2020, The results found that narcolepsy affects 0.87-1.21% of the world's population, specifically narcolepsy type 1 (NT1) being investigated. The rising prevalence of narcolepsy globally will lead to increased adoption of narcolepsy therapeutics in population to keep themselves active during the day, driving the market growth.
The approval and commercialization of new drugs by market players may also play a crucial role in driving market growth over the coming years. For instance, in March 2021, the United States Food and Drug Administration (FDA) accepted Avadel's New Drug Application (NDA) for FT218, an investigational, once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
However, delayed diagnosis or misdiagnosis may hamper the demand in the narcolepsy therapeutics market.
The Central Nervous System Stimulants segment is expected to hold a major share in the market during the forecast period.
According to an article published in CNS Drugs, titled 'Recently Approved and Upcoming Treatments for Narcolepsy', in January 2021, treatments such as modafinil, armodafinil, and other central nervous stimulants for narcolepsy are aimed at improving wakefulness in patients with narcolepsy.
Rising research on central nervous system stimulants is expected to drive the growth of this segment. For instance, in December 2021, Harmony Biosciences Holdings, Inc, a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, published the data analysis of CNS Drugs that evaluate the time to onset of response to pitolisant for excessive daytime sleepiness (EDS) and cataplexy in adult narcolepsy patients. Such studies will lead to novel central system stimulants' development, thereby driving this segment's growth.
Furthermore, according to the study published in Sleep Medicine and the Evolution of Contemporary Sleep Pharmacotherapy, titled 'Narcolepsy Treatment: Present and Future' in October 2021, The combination of modafinil with connexin-30 inhibitors is under development as this generates a stimulant effect within the central nervous system (CNS). The rise in the development of CNS stimulants for narcolepsy will lead to novel combination molecules coming into the market, thereby driving market growth.
In addition, according to the study published in Neurotherapeutics, titled 'A practical guide to the pharmacological and behavioral therapy of Narcolepsy 'in April 2021, modafinil, a CNS stimulant, has been approved by the Food and Drugs Administration and the European Medicines Agency (EMA) for adult narcolepsy patients and is regarded a good therapy due to its low potential for addiction and mild adverse effects.
Therefore, owing to the advantages of CNS stimulants in the treatment of narcolepsy, this segment is expected to drive the market over the forecast period.
North America is expected to hold a major share in the market studied during the forecast period.
This is owing to the growing demand for sleep disorder treatment in the United States and Canada. The increasing prevalence of narcoleptic disorders, increased awareness, and high healthcare spending is anticipated to drive the market. In addition, favorable reimbursement policies for therapeutic products, a strong clinical pipeline, and rising stress levels are the other factors anticipated to promote revenue growth.
According to the National Institute of Neurological Disorders and Stroke fact sheet updated in November 2021, narcolepsy affects anywhere between 135,000 and 200,000 people in the United States. However, because this ailment is frequently misdiagnosed, the figure could be much higher. The high prevalence of narcolepsy in developed countries such as the United States will lead to increased adoption of narcolepsy therapeutics, thereby driving the market growth in this region.
Furthermore, according to the news published in September 2021, Stanford researcher has proved that once-nightly narcolepsy treatment is safe and effective as a phase 3 study demonstrated that an extended-release variant of sodium oxybate lowers daytime sleepiness and attacks muscle weakness in narcolepsy patients. Rising effective results of narcolepsy treatments in the United States will lead to increased adoption of these therapies, thereby driving the growth of this market in this region.
In addition, in December 2021, Wake Up Narcolepsy, the charity group, received USD 1 million in donations for neurological research illnesses such as narcolepsy. The rise in donations for the development of narcolepsy treatments in the United States is further expected to drive the growth of this market in this region in the future.
All these factors are anticipated to bode well for the regional market's growth in the forthcoming years.
The narcolepsy therapeutics market is moderately competitive. Collaborations and acquisitions to share technology and costs for innovation in the field are expected to be observed. The market is driven due to the development of novel therapies and approval by international regulatory agencies. Some of the major players include companies, such as Avadel Pharmaceuticals Inc., Harmony Biosciences (BIOPROJET), Jazz Pharmaceuticals PLC, Ligand Pharmaceuticals Incorporated, Novartis, Shionogi Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceuticals USA Inc., among others
This product will be delivered within 2 business days.
COVID-19 has significantly impacted the market growth due to decreased adoption of narcolepsy therapeutics during the pandemic. For instance, according to the study published in the Journal of Clinical Sleep Medicine, titled 'Sleeping through a pandemic: impact of COVID-19-related restrictions on narcolepsy and idiopathic hypersomnia' in January 2022. extended sleep time, circadian delay (in Idiopathic Hypersomnia patients), and teleworking all reduced central hypersomnia symptoms. This has impacted the growth of the narcotic therapeutics market as there has been decreased consumption of narcolepsy therapeutics due to adequate sleep by people.
The increasing prevalence of narcoleptic disorders across the world, rising stress levels, growing geriatric population, and increasing awareness about various treatment options for this condition are some of the factors expected to propel the market. For instance, in the Journal of Clinical Sleep Medicine, titled 'Prevalence, incidence, and health care utilization of patients with narcolepsy: a population-representative study' in January 2022, the early incidence of narcolepsy in Europe is 0.64-1.37 per 100,000. The high incidence of this disorder will lead to increased adoption of narcolepsy therapies, thereby expected to drive the market growth over the forecast period.
In addition, according to the study published in Current Sleep Medicine Reports, titled 'Narcolepsy Presentation in Diverse Populations: an Update' in November 2020, The results found that narcolepsy affects 0.87-1.21% of the world's population, specifically narcolepsy type 1 (NT1) being investigated. The rising prevalence of narcolepsy globally will lead to increased adoption of narcolepsy therapeutics in population to keep themselves active during the day, driving the market growth.
The approval and commercialization of new drugs by market players may also play a crucial role in driving market growth over the coming years. For instance, in March 2021, the United States Food and Drug Administration (FDA) accepted Avadel's New Drug Application (NDA) for FT218, an investigational, once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
However, delayed diagnosis or misdiagnosis may hamper the demand in the narcolepsy therapeutics market.
Key Market Trends
Central Nervous System Stimulants Segment is Expected to Hold a Major Share During the Forecast Period
The Central Nervous System Stimulants segment is expected to hold a major share in the market during the forecast period.
According to an article published in CNS Drugs, titled 'Recently Approved and Upcoming Treatments for Narcolepsy', in January 2021, treatments such as modafinil, armodafinil, and other central nervous stimulants for narcolepsy are aimed at improving wakefulness in patients with narcolepsy.
Rising research on central nervous system stimulants is expected to drive the growth of this segment. For instance, in December 2021, Harmony Biosciences Holdings, Inc, a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, published the data analysis of CNS Drugs that evaluate the time to onset of response to pitolisant for excessive daytime sleepiness (EDS) and cataplexy in adult narcolepsy patients. Such studies will lead to novel central system stimulants' development, thereby driving this segment's growth.
Furthermore, according to the study published in Sleep Medicine and the Evolution of Contemporary Sleep Pharmacotherapy, titled 'Narcolepsy Treatment: Present and Future' in October 2021, The combination of modafinil with connexin-30 inhibitors is under development as this generates a stimulant effect within the central nervous system (CNS). The rise in the development of CNS stimulants for narcolepsy will lead to novel combination molecules coming into the market, thereby driving market growth.
In addition, according to the study published in Neurotherapeutics, titled 'A practical guide to the pharmacological and behavioral therapy of Narcolepsy 'in April 2021, modafinil, a CNS stimulant, has been approved by the Food and Drugs Administration and the European Medicines Agency (EMA) for adult narcolepsy patients and is regarded a good therapy due to its low potential for addiction and mild adverse effects.
Therefore, owing to the advantages of CNS stimulants in the treatment of narcolepsy, this segment is expected to drive the market over the forecast period.
North America is Expected to Hold a Significant Share in the Market
North America is expected to hold a major share in the market studied during the forecast period.
This is owing to the growing demand for sleep disorder treatment in the United States and Canada. The increasing prevalence of narcoleptic disorders, increased awareness, and high healthcare spending is anticipated to drive the market. In addition, favorable reimbursement policies for therapeutic products, a strong clinical pipeline, and rising stress levels are the other factors anticipated to promote revenue growth.
According to the National Institute of Neurological Disorders and Stroke fact sheet updated in November 2021, narcolepsy affects anywhere between 135,000 and 200,000 people in the United States. However, because this ailment is frequently misdiagnosed, the figure could be much higher. The high prevalence of narcolepsy in developed countries such as the United States will lead to increased adoption of narcolepsy therapeutics, thereby driving the market growth in this region.
Furthermore, according to the news published in September 2021, Stanford researcher has proved that once-nightly narcolepsy treatment is safe and effective as a phase 3 study demonstrated that an extended-release variant of sodium oxybate lowers daytime sleepiness and attacks muscle weakness in narcolepsy patients. Rising effective results of narcolepsy treatments in the United States will lead to increased adoption of these therapies, thereby driving the growth of this market in this region.
In addition, in December 2021, Wake Up Narcolepsy, the charity group, received USD 1 million in donations for neurological research illnesses such as narcolepsy. The rise in donations for the development of narcolepsy treatments in the United States is further expected to drive the growth of this market in this region in the future.
All these factors are anticipated to bode well for the regional market's growth in the forthcoming years.
Competitive Landscape
The narcolepsy therapeutics market is moderately competitive. Collaborations and acquisitions to share technology and costs for innovation in the field are expected to be observed. The market is driven due to the development of novel therapies and approval by international regulatory agencies. Some of the major players include companies, such as Avadel Pharmaceuticals Inc., Harmony Biosciences (BIOPROJET), Jazz Pharmaceuticals PLC, Ligand Pharmaceuticals Incorporated, Novartis, Shionogi Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceuticals USA Inc., among others
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Avadel Pharmaceuticals
- Harmony Biosciences (BIOPROJET)
- Jazz Pharmaceuticals PLC
- Ligand Pharmaceuticals Incorporated
- Novartis AG
- Shionogi Inc.
- Takeda Pharmaceutical Company
- Teva Pharmaceuticals Industries Ltd
- Axsome Therapeutics Inc.
- XWPharma Ltd.
Methodology
LOADING...
